1 |
P. Borst, "Genetic Mechanisms of Drug Resistance: A Review", Acta Oncol., Vol. 30, pp. 87-105, 1991.
DOI
ScienceOn
|
2 |
W. T. Bellamy and W. S. Dalton, "Multidrug resistance in the laboratory and clinic", Adv. Clin. Chem., Vol. 31, pp. 2-2, 1994.
|
3 |
D. W. Loe, R. G. Deeley, and S. P. Cole "Biology of the multidrug resistance-associated protein, MRP", Eur. J. Cancer, Vol. 32A, pp. 945-957, 1996.
|
4 |
M. Clynes, C. Daly, R. NicAmhlaoibh, D. Cronin, C. Elliott, R. O'Connor, T. O'Doherty, L. Connolly, A. Howlett, and K. Scanlon, "Recent developments in drug resistance and apoptosis research", Crit. Rev. Oncol. Hematol., Vol. 28, pp. 181-205, 1998.
DOI
ScienceOn
|
5 |
S. P. C. Cole and R. G. Deeley, "Multidrug resistance mediated by the ATP-binding cassette transporter protein MRP", Bioessays, Vol. 20, pp. 931-940, 1998.
DOI
ScienceOn
|
6 |
H. W. V. Veen and W. N. Konings, "Structure and function of multidrug transporters", Adv. Exp. Med. Biol. Vol. 456, pp. 145-158, 1998.
|
7 |
S. V. Ambudkar, S. Dey, C. A. Hrycyna, M. Ramachandra, I. Pastan, and M. M. Gottesman, "Biochemical, cellular, and pharmacological aspects of the multidrug transporter 1", Annu. Rev. Pharmacol. Toxicol., Vol. 39, pp. 361-398, 1999.
DOI
ScienceOn
|
8 |
P. Borst, R. Evers, M. Kool, and J. Wijnholds, "The multidrug resistance protein family", Biochim. Biophys. Acta Biomembr., Vol. 1461, pp. 347-357, 1999.
DOI
ScienceOn
|
9 |
D. R. Hipfner, R. G. Deeley, and S. P. C. Cole, "Structural, mechanistic and clinical aspects of MRP1", Biochim. Biophys. Acta Biomembr., Vol. 1461, pp. 359-376, 1999.
DOI
ScienceOn
|
10 |
J. Konig, A. T. Nies, Y. Cui, I. Leier, and D. Keppler, "Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance", Biochim. Biophys. Acta Biomembr., Vol. 1461, pp. 377-394, 1999.
DOI
ScienceOn
|
11 |
M. M. Gottesman, T. Fojo, and S. E. Bates, "Multidrug resistance in cancer: role of ATP-dependent transporters", Nat. Rev. Cancer, Vol. 2, pp. 48-58, 2002.
DOI
ScienceOn
|
12 |
M. M. Gottesman and I. Pastan, "Biochemistry of multidrug resistance mediated by the multidrug transporter", Annu. Rev. Biochem., Vol. 62, pp. 385-427, 1993.
DOI
ScienceOn
|
13 |
M. Dean, A. Rzhetsky, and R. Alliknets, "The human ATP binding cassette (ABC) transporter superfamily", Genome Res., Vol. 11, pp. 1156-1166, 2001.
DOI
ScienceOn
|
14 |
G. D. Leonard, T. Fojo, and S. E. Bates, "The role of ABC transporters in clinical practice", The Oncologist, Vol. 8, pp. 411-424, 2003.
DOI
ScienceOn
|
15 |
S. G. Aller, J. Yu, A. Ward, Y. Weng, S. Chittaboina, R. Zhuo, P. M. Harrell, Y. T. Trinh, Q. Zhang, and I. L. Urbatsch, "Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding", Science, Vol. 323, pp.1718-1722, 2009.
DOI
ScienceOn
|
16 |
D. Khare, M. L. Oldham, C. Orelle, A. L. Davidson, and J. Chen, "Alternating access in maltose transporter mediated by rigid-body rotations", Mol. cell, Vol. 33, pp. 528-536, 2009.
DOI
ScienceOn
|
17 |
K. Dano, "Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells", Biochim. Biophys. Acta, Vol. 323, pp. 466-483, 1973.
DOI
ScienceOn
|
18 |
T. W. Loo and D. M. Clarke, "The transmembrane domains of the human multidrug resistance P-glycoprotein are sufficient to mediate drug binding and trafficking to the cell surface", J. Biol. Chem., Vol. 274, pp. 24759-24765, 1999.
DOI
|
19 |
R. L. Juliano and V. Ling, "A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants", Biochim. Biophys. Acta Biomembr., Vol. 455, pp. 152-162, 1976.
DOI
ScienceOn
|
20 |
H. Venter, R. A. Shilling, S. Velamakanni, L. Balakrishnan, and H. W. van Veen, "An ABC transporter with a secondary-active multidrug translocator domain", Nature, Vol. 426, pp. 866-870, 2003.
DOI
ScienceOn
|
21 |
A. B. Shapiro and V. Ling, "Positively Cooperative Sites for Drug Transport by P Glycoprotein with Distinct Drug Specificities", Eur. J. Biochem., Vol. 250, pp. 130-137, 1997.
DOI
ScienceOn
|
22 |
A. B. Shapiro, K. Fox, P. Lam, and V. Ling, "Stimulation of P glycoprotein mediated drug transport by prazosin and progesterone", Eur. J. Biochem., Vol. 259, pp. 841-850, 1999.
|
23 |
C. Martin, G. Berridge, C. F. Higgins, P. Mistry, P. Charlton, and R. Callaghan, "Communication between multiple drug binding sites on P-glycoprotein", Mol. Pharmacol., Vol. 58, pp. 624-632, 2000.
DOI
|
24 |
T. W. Loo and D. M. Clarke, "Identification of residues within the drug-binding domain of the human multidrug resistance P-glycoprotein by cysteinescanning mutagenesis and reaction with dibromobimane", J. Biol. Chem., Vol. 275, pp. 39272-39278, 2000.
DOI
ScienceOn
|
25 |
T. W. Loo and D. M. Clarke, "Defining the drugbinding site in the human multidrug resistance Pglycoprotein using a methanethiosulfonate analog of verapamil, MTS-verapamil", J. Biol. Chem., Vol. 276, pp. 14972-14979, 2001.
DOI
ScienceOn
|
26 |
T. W. Loo and D. M. Clarke, "Location of the rhodamine-binding site in the human multidrug resistance P-glycoprotein", J. Biol. Chem., Vol. 277, pp. 44332-44338, 2002.
DOI
ScienceOn
|
27 |
R. J. P. Dawson and K. P. Locher, "Structure of a bacterial multidrug ABC transporter", Nature, Vol. 443, pp. 180-185, 2006.
DOI
ScienceOn
|
28 |
Z. E. Sauna and S. V. Ambudkar, "About a switch: how P-glycoprotein (ABCB1) harnesses the energy of ATP binding and hydrolysis to do mechanical work", Mol. Cancer Ther., Vol. 6, pp. 13, 2007.
|
29 |
R. J. P. Dawson and K. P. Locher, "Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP", FEBS letters, Vol. 581, pp. 935-938, 2007.
DOI
ScienceOn
|
30 |
C. F. Higgins and K. J. Linton, "The ATP switch model for ABC transporters", Nat. Struct. Mol. Biol., Vol. 11, pp. 918-926, 2004.
DOI
ScienceOn
|
31 |
T. W. Loo, M. C. Bartlett, and D. M. Clarke, "Simultaneous binding of two different drugs in the binding pocket of the human multidrug resistance P-glycoprotein", J. Biol. Chem., Vol. 278, pp. 39706-39710, 2003.
DOI
ScienceOn
|
32 |
S. Ayesh, Y. M. Shao, and W. D. Stein, "Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein", Biochim. Biophys. Acta, Mol. Basis Dis., Vol. 1316, pp. 8-18, 1996.
DOI
ScienceOn
|
33 |
T. W. Loo and D. M. Clarke, "Identification of residues in the drug-binding site of human P-glycoprotein using a thiol-reactive substrate", J. Biol. Chem., Vol. 272, pp. 31945-31948, 1997.
DOI
ScienceOn
|
34 |
T. W. Loo, M. C. Bartlett, and D. M. Clarke, "Transmembrane segment 7 of human P-glycoprotein forms part of the drug-binding pocket", Biochem. J., Vol. 399, pp. 351-359, 2006.
DOI
ScienceOn
|
35 |
C. H. Choi, "ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal", Cancer Cell Int., Vol. 5, pp. 30, 2005.
DOI
|
36 |
M. L. Veigl, T. C. Vanaman, and W. D. Sedwick, "Calcium and calmodulin in cell growth and transformation", Biochim. Biophys. Acta, Vol. 738, pp. 21-48, 1984.
|
37 |
M. J. Borgnia, G. D. Eytan, and Y. G. Assaraf, "Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity", J. Biol. Chem., Vol. 271, pp. 3163-3171, 1996.
DOI
|
38 |
J. M. Ford and W. N. Hait, "Pharmacology of drugs that alter multidrug resistance in cancer", Pharmacol. Rev., Vol. 42, pp. 155-199, 1990.
|
39 |
R. Krishna and L. D. Mayer, "Multidrug resistance (MDR) in cancer:: Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs", Eur. J. Pharm. Sci., Vol. 11, pp. 265-283, 2000.
DOI
ScienceOn
|
40 |
D. R. Ferry, H. Traunecker, and D. J. Kerr, "Clinical trials of P-glycoprotein reversal in solid tumours", Eur. J. Cancer, Vol. 32, pp. 1070-1081, 1996.
DOI
ScienceOn
|
41 |
J. G. W. Theis, H. S. L. Chan, M. L. Greenberg, D. Malkin, V. Karaskov, I. Moncica, G. Koren, and J. Doyle, "Assessment of systemic toxicity in children receiving chemotherapy with cyclosporine for sarcoma", Med. Pediatr. Oncol., Vol. 34, pp. 242-249, 2000.
DOI
ScienceOn
|
42 |
P. A. W. Boekhorst, J. Kapel, M. Schoester, and P. Sonneveld, "Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing themdr1 phenotype", Cancer Chemother. Pharmacol., Vol. 30, pp. 238-242, 1992.
DOI
ScienceOn
|
43 |
P. R. Twentyman and N. M. Bleehen, "Resistance modification by PSC-833, a novel non-immunosuppressive cyclosporin A", Eur. J. Cancer Clin. Oncol., Vol. 27, pp. 1639-1642, 1991.
DOI
|
44 |
H. Thomas and H. M. Coley, "Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein", Cancer Control, Vol. 10, pp. 159-159, 2003.
DOI
|
45 |
B. L. Lum and M. P. Gosland, "MDR expression in normal tissues: pharmacologic implications for the clinical use of P-glycoprotein inhibitors", Hematol. Oncol North Am., Vol. 9, pp. 319-336, 1995.
|
46 |
C. Wandel, "P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies", Cancer Res., Vol. 59, pp. 3944-3948, 1999.
|
47 |
S. Bates, M. Kang, B. Meadows, S. Bakke, P. Choyke, M. Merino, B. Goldspiel, I. Chico, T. Smith, and C. Chen, "A Phase I study of infusional vinblastine in combination with the p glycoprotein antagonist PSC 833 (valspodar)", Cancer, Vol. 92, pp. 1577-1590, 2001.
DOI
ScienceOn
|
48 |
K. D. Bunting, "ABC transporters as phenotypic markers and functional regulators of stem cells", Stem Cells, Vol. 20, pp. 11-20, 2002.
DOI
ScienceOn
|
49 |
E. K. Rowinsky, L. Smith, Y. M. Wang, P. Chaturvedi, M. Villalona, E. Campbell, C. Aylesworth, S. G. Eckhardt, L. Hammond, and M. Kraynak, "Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP", J. Clin. Oncol., Vol. 16, pp. 2964-2976, 1998.
DOI
|
50 |
T. Yanagisawa, A. Newman, H. Coley, J. Renshaw, C. R. Pinkerton, and K. Pritchard-Jones, "BIRICO-DAR (VX-710; ): an effective chemosensitizer in neuroblastoma", Br. J. Cancer, Vol. 80, pp. 1190-1196, 1999.
DOI
|
51 |
A. H. Dantzig, R. L. Shepard, K. L. Law, L. Tabas, S. Pratt, J. S. Gillespie, S. N. Binkley, M. T. Kuhfeld, J. J. Starling and S. A. Wrighton, "Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities", J. Pharmacol. Exp. Ther., Vol. 290, pp. 854-862, 1999.
|
52 |
C. Wandel, R. B. Kim, S. Kajiji, P. Guengerich, G. R. Wilkinson, and A. J. Wood, "P-Glycoprotein and cytochrome P-450 3A inhibition: Dissociation of inhibitory Potencies", Cancer Res., Vol. 59, pp. 3944-3948, 1999.
|
53 |
C. Martin, G. Berridge, P. Mistry, C. Higgins, P. Charlton, and R. Callaghan, "The molecular interaction of the high affinity reversal agent XR9576 with P glycoprotein", Br. J. Pharmacol., Vol. 128, pp. 403-411, 1999.
DOI
ScienceOn
|
54 |
A. H. Dantzig, K. L. Law, J. Cao, and J. J. Starling, "Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic", Curr. Med. Chem., Vol. 8, pp. 39-50, 2001.
DOI
ScienceOn
|
55 |
M. Roe, A. Folkes, P. Ashworth, J. Brumwell, L. Chima, S. Hunjan, I. Pretswell, W. Dangerfield, H. Ryder, and P. Charlton, "Reversal of P-glycoprotein mediated multidrug resistance by novel anthranilamide derivatives", Bioorg. Med. Chem. Lett., Vol. 9, pp. 595-600, 1999.
DOI
ScienceOn
|
56 |
C. Martin, G. Berridge, P. Mistry, C. Higgins, P. Charlton, and R. Callaghan, "The molecular interaction of the high affinity reversal agent XR9576 with P glycoprotein", Br. J. Pharmacol., Vol. 128, pp. 403-411, 1999.
DOI
ScienceOn
|
57 |
L. D. Cripe, M. Tallman and C. Karanes, "A phase II trial of zosuquidar (LY335979), a modulator of P-glycoprotein (P-gp) activity, plus daunorubicin and high-dose cytarabine in patients with newly-diagnosed secondary acute myeloid leukemia (AML), refractory anemia with excess blasts in transformation (RAEB-t), or relapsed/refractory AML", Blood, Vol. 98, pp. 595a, 2001.
|
58 |
A. H. Dantzig, R. L. Shepard, J. Cao, K. L. Law, W. J. Ehlhardt, T. M. Baughman, T. F. Bumol, and J. J. Starling, "Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979", Cancer Res., Vol. 56, pp. 4171-4179, 1996.
|
59 |
J. J. Starling, R. L. Shepard, J. Cao, K. L. Law, B. H. Norman, J. S. Kroin, W. J. Ehlhardt, T. M. Baughman, M. A. Winter, and M. G. Bell, "Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein", Adv. Enzyme Regul., Vol. 37, pp. 335-347, 1997.
DOI
|
60 |
A. H. Dantzig, R. L. Shepard, K. L. Law, L. Tabas, S. Pratt, J. S. Gillespie, S. N. Binkley, M. T. Kuhfeld, J. J. Starling and S. A. Wrighton, "Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities", J. Pharmacol. Exp. Ther., Vol. 290, pp. 854-862, 1999.
|
61 |
S. Tura, F. Morschhauser, P. Zinzani, L. Sloots, M. Burgess and C. Dumontet, "A phase I trial of the P-glycoprotein (Pgp) inhibitor zosuquidar (LY335979) and CHOP chemotherapy in patients with non-Hodgkin's lymphoma", Blood, Vol. 98, pp. 251 2001.
DOI
ScienceOn
|